$77.59
+1.6%Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Outstanding operational efficiency. The company generates substantial profit from core operations.
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
ZTS โข NYSE
| Zoetis Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||||
9.5B | 9.3B | 8.5B | 8.1B | 7.8B | 6.7B | 6.3B | 5.8B | 5.3B | 4.9B | 4.8B | 4.8B | 4.6B | 4.3B | 4.2B | 3.6B | 2.8B | |
GROSS PROFIT | |||||||||||||||||
(2.8B) | (2.9B) | (2.7B) | (2.6B) | (2.5B) | (2.2B) | (2.1B) | (2B) | (1.9B) | (1.7B) | (1.8B) | (1.8B) | (1.7B) | (1.6B) | (1.7B) | (1.5B) | (1.1B) | |
6.7B | 6.4B | 5.8B | 5.5B | 5.3B | 4.5B | 4.1B | 3.8B | 3.4B | 3.1B | 3B | 3B | 2.8B | 2.7B | 2.5B | 2.1B | 1.7B | |
OPERATING INCOME | |||||||||||||||||
(3.1B) | (3B) | (2.8B) | (2.5B) | (2.5B) | (2.2B) | (2.1B) | (1.9B) | (1.7B) | (1.7B) | (1.9B) | (2B) | (2B) | (1.9B) | (1.9B) | (1.8B) | (1.4B) | |
(2.4B) | (2.3B) | (2.2B) | (2B) | (2B) | (1.7B) | (1.6B) | (1.5B) | (1.3B) | (1.3B) | (1.4B) | (1.5B) | (1.4B) | (1.5B) | (1.5B) | (1.4B) | (1.1B) | |
(698M) | (686M) | (614M) | (539M) | (508M) | (463M) | (457M) | (432M) | (382M) | (376M) | (364M) | (396M) | (399M) | (409M) | (427M) | (411M) | (368M) | |
3.6B | 3.4B | 3.1B | 2.9B | 2.8B | 2.3B | 2B | 1.9B | 1.7B | 1.4B | 1.1B | 970M | 821M | 854M | 684M | 309M | 281M | |
PRE-TAX INCOME | |||||||||||||||||
(243M) | (242M) | (258M) | (237M) | (236M) | (249M) | (242M) | (212M) | (175M) | (166M) | (124M) | (117M) | (113M) | (31M) | (36M) | (37M) | (26M) | |
-150M | -136M | -153M | -187M | -230M | -237M | -205M | -181M | -175M | -166M | -124M | -117M | -113M | -31M | -36M | -37M | -26M | |
-237M | -259M | -133M | -272M | -315M | -273M | -217M | -191M | -202M | -176M | -537M | -150M | -133M | -144M | -290M | -131M | -429M | |
3.4B | 3.1B | 2.9B | 2.7B | 2.5B | 2B | 1.8B | 1.7B | 1.5B | 1.2B | 545M | 820M | 690M | 710M | 394M | 178M | -148M | |
NET INCOME | |||||||||||||||||
(687M) | (637M) | (596M) | (545M) | (454M) | (360M) | (301M) | (266M) | (663M) | (409M) | (206M) | (233M) | (187M) | (274M) | (146M) | (67M) | -47M | |
2.7B | 2.5B | 2.3B | 2.1B | 2B | 1.6B | 1.5B | 1.4B | 864M | 821M | 339M | 583M | 504M | 436M | 245M | 110M | -100M |
ZTS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 20, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 08, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | February 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 15, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 11, 2025 | 2025 |
Continue your ZTS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.